Leading articleInfliximab (Remicade ®): the magic bullet for Crohn's disease?
References (20)
- et al.
The mouse/human chimeric monoclonal antibody cA2 neutralizes in vitro and protects transgenic mice from cachexia and TNF-α lethality in vivo
Cytokine
(1995) - et al.
Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
Cytokine
(1995) - et al.
Endoscopic and histological healing with infliximab antibodies in Crohn's disease: a European multicenter trial
Gastroenterology
(1999) - et al.
Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
Gastroenterology
(1999) - et al.
Infliximab (Remicade®) for treatment of perineal metastatic Crohn's disease
Gastroenterology
(2000) - et al.
Infliximab for Crohn's disease in clinical practice at the Mayo clinic: the first 100 patients
Gastroenterology
(2000) - et al.
Complete bowel obstruction following initial response to infliximab therapy: a series of a newly described complication
Gastroenterology
(2000) - et al.
A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease
J Immunol
(1997) - et al.
Enhanced secretion of tumor necrosis factor-alpha, IL-6 and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
Clin Exp Immunol
(1993) The role of tumor necrosis factor in health and disease
J Rheumatol
(1999)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2000 Published by Elsevier Ltd.